NASDAQ:CNCE

Concert Pharmaceuticals Stock Forecast, Price & News

$11.37

+0.35 (+3.18 %)

(As of 11/27/2020 12:00 AM ET)

Add

Compare

Today's Range

$10.62

Now: $11.37▼

$11.73

50-Day Range

$9.48

MA: $11.03▼

$12.08

52-Week Range

$5.47

Now: $11.37▼

$13.09

Volume78,315 shs

Average Volume152,080 shs

Market Capitalization$348.48 million

P/E RatioN/A

Dividend YieldN/A

Beta0.77

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company also have license agreement with Cipla Technologies. Concert Pharmaceuticals was founded in 2006 and is headquartered in Lexington, Massachusetts.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Concert Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.83, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.40, Concert Pharmaceuticals has a forecasted upside of 88.2% from its current price of $11.37.
Amount of Analyst Coverage
Concert Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Concert Pharmaceuticals has received 499 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Concert Pharmaceuticals has received 423 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Concert Pharmaceuticals has received 54.12% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote “Outperform” if you believe CNCE will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Concert Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Concert Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Concert Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 11.00% of the stock of Concert Pharmaceuticals is held by insiders.
Percentage Held by Institutions
66.31% of the stock of Concert Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Concert Pharmaceuticals are expected to grow in the coming year, from ($2.55) to ($2.53) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Concert Pharmaceuticals is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Concert Pharmaceuticals is -4.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Concert Pharmaceuticals has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.68 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:CNCE

Previous Symbol

CUSIPN/A

CIK1367920

Webwww.concertpharma.com

Phone781-860-0045

Employees70

Debt

Debt-to-Equity RatioN/A

Current Ratio18.51

Quick Ratio18.51

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$1.08 million

Price / Sales322.67

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.17 per share

Price / Book2.73

Profitability

EPS (Most Recent Fiscal Year)($3.29)

Net Income$-78,170,000.00

Net Margins-921.38%

Return on Equity-55.20%

Return on Assets-44.83%

Miscellaneous

Outstanding Shares30,649,000

Market Cap$348.48 million

Next Earnings Date2/25/2021 (Estimated)

OptionableOptionable

$11.37

+0.35 (+3.18 %)

(As of 11/27/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

How has Concert Pharmaceuticals' stock been impacted by COVID-19?

Concert Pharmaceuticals' stock was trading at $8.35 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CNCE stock has increased by 36.2% and is now trading at $11.37.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Concert Pharmaceuticals?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Concert Pharmaceuticals.

What stocks does MarketBeat like better than Concert Pharmaceuticals?

Wall Street analysts have given Concert Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Concert Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Concert Pharmaceuticals.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) announced its quarterly earnings results on Thursday, November, 5th. The biotechnology company reported ($0.60) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.15. Concert Pharmaceuticals had a negative return on equity of 55.20% and a negative net margin of 921.38%.
View Concert Pharmaceuticals' earnings history.

What price target have analysts set for CNCE?

6 Wall Street analysts have issued 1 year price targets for Concert Pharmaceuticals' shares. Their forecasts range from $11.00 to $30.00. On average, they expect Concert Pharmaceuticals' stock price to reach $21.40 in the next twelve months. This suggests a possible upside of 88.2% from the stock's current price.
View analysts' price targets for Concert Pharmaceuticals.

Who are some of Concert Pharmaceuticals' key competitors?

Some companies that are related to Concert Pharmaceuticals include Ligand Pharmaceuticals (LGND), Athenex (ATNX), MacroGenics (MGNX), Rhythm Pharmaceuticals (RYTM), Phathom Pharmaceuticals (PHAT), Ocular Therapeutix (OCUL), Kiniksa Pharmaceuticals (KNSA), Endo International (ENDP), Epizyme (EPZM), Intercept Pharmaceuticals (ICPT), Constellation Pharmaceuticals (CNST), Amneal Pharmaceuticals (AMRX), Cytokinetics (CYTK), Travere Therapeutics (RTRX) and Zogenix (ZGNX).
View all competitors.

What other stocks do shareholders of Concert Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Concert Pharmaceuticals investors own include Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Exelixis (EXEL), ACADIA Pharmaceuticals (ACAD), Nektar Therapeutics (NKTR), TG Therapeutics (TGTX), Celldex Therapeutics (CLDX), Amicus Therapeutics (FOLD), Global Blood Therapeutics (GBT) and Intel (INTC).

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the following people:

Mr. Richard H. Aldrich M.B.A., Mba, Co-Founder & Chairman (Age 66, Pay $83.52k)
Dr. Roger D. Tung, Co-Founder, CEO, Pres & Exec. Director (Age 60, Pay $882.85k)
Mr. Marc A. Becker, CFO & Principal Accounting Officer (Age 48, Pay $559.68k)
Dr. James V. Cassella, Chief Devel. Officer (Age 65, Pay $667.08k)
Ms. Nancy Stuart, Chief Operating Officer (Age 62)
Ms. Justine E. Koenigsberg, Sr. VP of Corp. Communications and Investor Relations
Mr. Jeffrey A. Munsie, Chief Legal Officer & Corp. Sec. (Age 43)
Dr. Ian Robert Silverman J.D., Ph.D., Sr. Legal Advisor (Age 67)

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (6.12%), Ingalls & Snyder LLC (4.59%), Point72 Asset Management L.P. (2.53%), State Street Corp (1.67%), Connor Clark & Lunn Investment Management Ltd. (1.12%) and Sphera Funds Management LTD. (1.01%). Company insiders that own Concert Pharmaceuticals stock include Bvf Partners L P/Il, Heek Christi Van, Nancy Stuart, Peter Barton Hutt and Thomas G Auchincloss.
View institutional ownership trends for Concert Pharmaceuticals.

Which major investors are selling Concert Pharmaceuticals stock?

CNCE stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Acadian Asset Management LLC, Wells Fargo & Company MN, WINTON GROUP Ltd, Ingalls & Snyder LLC, Dupont Capital Management Corp, Connor Clark & Lunn Investment Management Ltd., and JPMorgan Chase & Co..
View insider buying and selling activity for Concert Pharmaceuticals.

Which major investors are buying Concert Pharmaceuticals stock?

CNCE stock was acquired by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., GSA Capital Partners LLP, Arrowstreet Capital Limited Partnership, Squarepoint Ops LLC, Jane Street Group LLC, AXA S.A., State Street Corp, and BNP Paribas Arbitrage SA. Company insiders that have bought Concert Pharmaceuticals stock in the last two years include Heek Christi Van, and Thomas G Auchincloss.
View insider buying and selling activity for Concert Pharmaceuticals.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $11.37.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $348.48 million and generates $1.08 million in revenue each year. The biotechnology company earns $-78,170,000.00 in net income (profit) each year or ($3.29) on an earnings per share basis. Concert Pharmaceuticals employs 70 workers across the globe.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is www.concertpharma.com.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings